Skip to content

Glyceryl Trinitrate Versus Lidocaine Cream for IUD Insertion

Topical Glyceryl Trinitrate Versus Lidocaine Cream as Analgesia for IUD Insertion: A Randomized Controlled Trial

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02708251
Acronym
GTN-IUD
Enrollment
150
Registered
2016-03-15
Start date
2016-10-31
Completion date
2017-06-30
Last updated
2017-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IUD Insertion

Brief summary

The intrauterine device (IUD) is a long-acting, highly effective, reversible contraceptive method that may be underutilized due to fear of pain during insertion. Although providers frequently prescribe non-steroidal anti-inflammatory drugs (NSAIDs) for IUD insertion, there is no evidence for any pain reduction. Women can experience high levels of pain when the IUD is placed inside the uterus, and fear of this pain could be a reason that women decide not to use this method.

Interventions

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 49 Years
Healthy volunteers
No

Inclusion criteria

1. Women not taken analgesics or anxiolytics in the 24 hours prior insertion 2. Women not taken misoprostol prior to IUD insertion 3. No contraindication to or history of allergic reaction to lidocaine or NO donors. 4. Women who will accept to participate in the study

Exclusion criteria

1. Lidocaine allergy 2. History of migraine or chronic headache 3. Any contraindication to IUD placement

Design outcomes

Primary

MeasureTime frame
Mean pain score during IUD insertion3 minutes

Secondary

MeasureTime frame
Patient satisfaction score after the procedure3 minutes

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 3, 2026